Affiliation:
1. The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China
2. Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Abstract
Abstract:
Metformin is a first-line drug for the treatment of type 2 diabetes with a good
safety profile and relatively low cost. In recent years, many other effects of metformin
have been discovered. In this review, we provide the research advances in metformin in
liver disease. High-dose metformin can activate AMPK by inhibiting mitochondrial complex 1. In addition, low-dose metformin could activate lysosomal AMPK through PEN2.
Activated AMPK can reduce fatty acid synthesis, inhibit tumor proliferation and metastasis, and reshape the tumor microenvironment. In addition, metformin can reduce ROS
production by inhibiting mitochondrial complex 1, which can reduce liver damage.
Therefore, metformin has been found to alleviate nonalcoholic fatty liver disease and cirrhosis, relieve liver damage, and reduce the incidence of hepatocellular carcinoma and
cholangiocarcinoma. This information suggests that metformin may represent a new possibility for the prevention and treatment of liver diseases
Publisher
Bentham Science Publishers Ltd.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献